Recent studies have shown that the cellular expression of Sestrin2, which belongs to the SESN family, increases during chemotherapy for osteosarcoma, which in turn inhibits PERK-eIF2α-CHOP activation, leading to a decrease in CHOP-induced apoptosis. Here, DDIT3 is linked to osteosarcoma.